From e5951f3fc0b7c4de28d8926ee696e45b61531cd9 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 13:30:14 +0000 Subject: [PATCH] extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...et cost impact inflationary through 2035.md | 6 ++++++ ...y-cardiovascular-and-metabolic-endpoints.md | 6 ++++++ ...reating-largest-per-patient-cost-savings.md | 6 ++++++ ...le conditions faster than prices decline.md | 6 ++++++ ...hensive-semaglutide-medicare-economics.json | 8 ++++---- ...rehensive-semaglutide-medicare-economics.md | 18 +++++++++++++++++- 6 files changed, 45 insertions(+), 5 deletions(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 8a55608ba..d4a45d3ca 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -113,6 +113,12 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent. + +### Additional Evidence (challenge) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19* + +Medicare-specific modeling shows net savings of $715M over 10 years when multi-indication benefits are comprehensively accounted for, with T2D-related savings ($892M) exceeding obesity-related costs ($205M). This challenges the universal 'inflationary through 2035' framing by demonstrating that payer-level economics under risk-bearing arrangements can diverge from system-level cost impact. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index f02739da1..6a37c35df 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -66,6 +66,12 @@ Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 Aon's 192K patient study found adherent GLP-1 users (80%+) had 47% fewer MACE hospitalizations for women and 26% for men, with the sex differential suggesting larger cardiovascular benefits for women than previously documented. + +### Additional Evidence (confirm) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19* + +Medicare modeling quantifies multi-organ protection value: $14,431/subject in avoided T2D costs, $2,074/subject in avoided CKD costs, $1,512/subject in avoided CV event costs. Over 10 years, 38,950 cardiovascular events avoided and 6,180 deaths prevented, with per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index fa9337843..d4697a471 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -46,6 +46,12 @@ SELECT trial economic model shows $2,074 per-subject lifetime savings from avoid In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy. + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19* + +Medicare modeling shows CKD-related savings of $2,074 per subject treated, which is smaller than T2D-related savings ($14,431/subject) but still material. The 10-year window captures dialysis delay benefits but may underestimate lifetime value since dialysis costs compound over decades. + --- Relevant Notes: diff --git a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md index 5d8743dc9..63ea5d945 100644 --- a/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md +++ b/domains/health/the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md @@ -43,6 +43,12 @@ The composition of spending shifts dramatically: less on chronic disease managem The Medicare semaglutide analysis provides a boundary condition: when payment is integrated and multi-indication benefits compound, prevention CAN bend the cost curve down for specific payers. However, this requires: (1) single entity bearing costs and capturing savings, (2) multi-indication efficacy across high-cost conditions, (3) sufficient persistence to realize benefits. The system-level curve may still bend up while risk-bearing integrated payers see net savings—a payment structure divergence. + +### Additional Evidence (extend) +*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-19* + +Semaglutide demonstrates the mechanism: even when a single treatment saves money for a unified payer ($715M Medicare savings over 10 years), this requires comprehensive multi-indication use that increases total treatment volume. The 'cost curve bends up' claim holds at system level even as individual payer economics can be favorable under risk-bearing arrangements. + --- Relevant Notes: diff --git a/inbox/queue/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json b/inbox/queue/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json index 9dbec870b..6ed7e0f15 100644 --- a/inbox/queue/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json +++ b/inbox/queue/.extraction-debug/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.json @@ -1,7 +1,7 @@ { "rejected_claims": [ { - "filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md", + "filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md", "issues": [ "missing_attribution_extractor" ] @@ -13,12 +13,12 @@ "fixed": 1, "rejected": 1, "fixes_applied": [ - "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:set_created:2026-03-18" + "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md:set_created:2026-03-19" ], "rejections": [ - "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:missing_attribution_extractor" + "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-under-unified-payer.md:missing_attribution_extractor" ] }, "model": "anthropic/claude-sonnet-4.5", - "date": "2026-03-18" + "date": "2026-03-19" } \ No newline at end of file diff --git a/inbox/queue/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md b/inbox/queue/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md index 2af4451db..50e41f077 100644 --- a/inbox/queue/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md +++ b/inbox/queue/2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics.md @@ -7,13 +7,17 @@ date: 2025-06-01 domain: health secondary_domains: [internet-finance] format: paper -status: unprocessed +status: enrichment priority: high tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH] processed_by: vida processed_date: 2026-03-18 enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"] extraction_model: "anthropic/claude-sonnet-4.5" +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -55,3 +59,15 @@ EXTRACTION HINT: Focus on the distinction between system-level cost impact (infl - Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided - Average per-subject lifetime treatment costs: $47,353 - Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject + + +## Key Facts +- Medicare semaglutide modeling projects net savings of $715M over 10 years (range: $412M to $1.04B) +- T2D-related semaglutide impact: $892M savings over 10 years +- Obesity-related semaglutide impact: $205M added costs over 10 years +- MASH-related semaglutide impact: $28M savings over 10 years +- 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access +- 6,180 deaths avoided (CV + CKD/MASH progression) +- Average per-subject lifetime semaglutide treatment costs: $47,353 +- Per-subject savings: $14,431 (T2D), $2,074 (CKD), $1,512 (CV events) +- Per 100,000 subjects: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided